Illuminating the immune interface to develop new cancer therapies
The Enara Bio™ purpose
Shining a light on Dark Antigen™ and T-cell biology to enable people to live free from the shadow of cancer.
Enara Bio is exploring the hidden depths of cancer biology to discover and characterize novel immunotherapy targets, such as Dark Antigens derived from the genomic dark matter or cancer-specific antigens presented by MR1.
To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.
Read more about usOur team
We have established a core team of scientists, entrepreneurs and industry veterans to drive our research, development and clinical success.
View team
Kevin Pojasek
President and Chief Executive Officer
Joseph Dukes
Vice President, Translational Science
David Watson
Chief Operating Officer
Latest News
-
Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit
Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June.
-
Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team
Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research
Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research
-
Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach.
